To identify infants at risk of death and abnormal neurodevelopmental outcome following extracorporeal membrane oxygenation (ECMO) in the neonatal period.
Extracorporeal membrane oxygenation (ECMO) has been used as a treatment strategy in nearly 10,000 newborns since the mid-1970s for term and near term infants in severe respiratory failure. 1 The presence of severe respiratory failure and associated hemodynamic instability places these infants at high risk for central nervous system injury. The necessity for right common carotid artery ligation and for systemic anticoagulation during ECMO potentially increases this risk. The results of follow-up studies reporting the outcome of ECMO survivors suggest that a significant number of these infants are at risk of neurodevelopmental disability. [2] [3] [4] [5] [6] [7] [8] [9] [10] An early identification of the subgroup of infants at highest risk of subsequent neurodevelopmental impairment would allow caregivers to restructure services and focus them on the needs of these "at risk" infants.
The aim of this study was to identify infants at risk of death and abnormal neurodevelopmental outcome following neonatal ECMO.
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brain were performed after extubation and before discharge from the neonatal intensive care unit. It had been our practice to perform these neuroimaging studies on all ECMO infants before their discharge, and none of these studies were part of a research protocol.
Perinatal Variables
The following demographic data were collected: gestational age, birth weight, race, gender, and insurance status. The following information was also evaluated for each study subject: primary diagnosis, 1-and 5-minute Apgar scores, lowest PaO 2 , lowest PaCO 2 , pre-ECMO oxygenation index (OI), duration of ventilation, oxygen supplementation and gavage feeding. Feedings were initiated as soon as permitted by the infant's condition. An effort was made to nipple feed as tolerated by the infant. Stimulation of oromotor skills was provided to the infants who failed to establish nipple feedings on their own.
Neurodevelopmental Assessment
All survivors of ECMO were enrolled in a follow-up program at discharge. The infants were followed at 3, 6, and 12 months of age during the first year and yearly thereafter. The height, weight, and head circumferences were measured at each visit. The Bayley Scales of Infant Development 11 were performed at each visit between 12 and 30 months of age and the McCarthy Scales of Children's Abilities 12 were performed at each visit after 30 months until 5 years of age. A complete physical examination, including a detailed neurologic examination was conducted by a physician on each visit. The neurologic and developmental outcomes were defined as previously described. 13 The neurologic outcome was defined as follows: "normal" if there were no abnormalities on neurologic examination and developmental milestones were appropriate for age; "suspect" if there were abnormalities on the examination that did not interfere with achieving motor milestones; and "abnormal" if there were abnormalities on the neurologic examination that resulted in delays in achieving age-appropriate milestones. The developmental outcome was defined as "normal" if the mental developmental index (MDI) or general cognitive index (GCI) was greater than 1 SD below the mean (Ն84), "suspect" if the MDI or GCI was between 1 and 2 SD below the mean (68 to 83), and "abnormal" if the MDI or GCI was more than 2 SD below the mean (Յ67). An infant with normal neurologic and normal developmental outcome is considered to have a normal neurodevelopmental outcome. An infant with suspect outcome on neurologic and/or cognitive assessment is reported to have suspect neurodevelopmental outcome; an infant with abnormal outcome on neurologic and/or cognitive assessment is reported to have an abnormal neurodevelopmental outcome.
Statistical Analysis
Data are presented as number of patient and mean Ϯ SEM unless otherwise noted. Statistical comparisons are made with a t test for continuous data and a -squared test for categorical data. The relationship between various risk factors, survival, and neurodevelopmental outcome was evaluated using the Kruskal-Wallis one-way analysis of variance test or the Mann-Whitney U test. The relative risk and 95% confidence limits are reported. A p value of less than 0.05 was considered significant.
RESULTS
Between January 1988 and December 1991, 82 infants required ECMO for respiratory failure due to nonsurgical and noncardiac causes at our institution. Seventy-seven of 82 infants had venoarterial ECMO, and five infants had venovenous bypass. None of the infants underwent post-ECMO carotid repair.
Neonatal Outcome
The overall survival for this group of 82 infants was 91% (75 of 82). Survival rates for major primary diagnoses were: meconium aspiration syndrome, 96%; hyaline membrane disease, 80%; sepsis, 78%; and idiopathic persistent pulmonary hypertension, 80%. Demographic and clinical characteristics of the survivors and nonsurvivors are listed in Table 1 . The mean gestational age of survivors was 40 Ϯ 0 weeks as compared with 37.0 Ϯ 1 weeks among nonsurvivors ( p Ͻ 0.005). The mean birth weight of survivors was also significantly higher than that of nonsurvivors ( p Ͻ 0.01). The race, gender distribution, and primary diagnoses of the infants in the two groups were comparable. The major primary diagnoses in seven nonsurvivors were: meconium aspiration syndrome, 2; hyaline membrane disease, 2; sepsis, 2; and idiopathic persistent pulmonary hypertension, 1. There were no differences in the 1-and 5-minute Apgar scores, lowest PaO 2 , lowest PaCO 2 , and pre-ECMO OI between the two groups ( Table 1) . 
Follow-up
Of 75 ECMO survivors, 63 infants (84%) were followed for 12 months or more in our follow-up program. Twelve infants (16%) were lost to follow-up. The infants with follow-up did not differ from those with no follow-up in any of the demographic variables or clinical indicators of illness severity (Table 2) .
Neurodevelopmental Outcome
Nine of these 63 infants were followed for 5 years, while 8, 17, 14, and 15 infants had 4-, 3-, 2-, and 1-year follow-up, respectively (Table 3) . Neurologic outcome at the last follow-up visit was normal in 51 (81%) infants, suspect in 4 (6.0%), and abnormal in 8 (13%) infants. The abnormalities observed in eight infants with abnormal neurologic outcome included: quadriparesis, 3; spastic diplegia, 2; hemiparesis, 2; and monoparesis, 1. Developmental outcome was normal in 40 (63%), suspect in 14 (23%), and abnormal in 9 (14%) infants (Table 3) . Thirty-five of 63 infants (56%) were normal on both neurologic and developmental examination at the time of the last followup. Thirteen infants (21%) had abnormal neurodevelopmental outcome, and the remaining 15 infants (24%) were suspect. To evaluate risk of abnormal outcome, we compared the characteristics of infants with normal, suspect, and abnormal neurodevelopmental outcome (Table 4) . Gestational age, birth weight, gender distribution, insurance status, number of infants with low 5-minute Apgar scores were comparable among infants with normal, suspect, and abnormal neurodevelopmental outcome ( 
A longer duration of ventilation was significantly associated with abnormal neurodevelopmental outcome in these infants ( p ϭ 0.002, Table 4 ). The data were further analyzed to assess the likelihood of an abnormal neurodevelopmental outcome if an infant required ventilatory support for more than 14 days or supplemental oxygenation for more than 21 days. Infants requiring ventilatory support for 15 days or more were more likely to have an abnormal neurodevelopmental outcome then were infants with duration of ventilation of 14 days or less (RR 5.5; 95% CI 2.0 to 14.8). Ventilatory support for 15 days or more was needed in 69% (9 of 13) of infants with abnormal neurodevelopmental outcome, 40% (6 of 15) of those with a suspect neurodevelopmental outcome, and 14% (5 of 35) of normal infants ( p ϭ 0.001). Infants requiring supplemental oxygen for 22 days or more were at significantly higher risk of having an abnormal outcome (RR 3.1; 95% CI 1.3 to 7.6). Supplemental oxygen for 22 days or more was required by 54% (7 of 13) of infants with abnormal neurodevelopmental outcome as compared with 40% (6 of 15) of suspect infants and 21% (6 of 35) of normal infants ( p ϭ 0.01). The incidence of abnormal neuroimaging studies was similar among infants with normal, suspect, and abnormal neurodevelopmental outcome (Table  4 ). An analysis of infants with normal and abnormal neurodevelopmental outcome revealed that none of the neuroimaging studies were helpful in accurately predicting the neurodevelopmental outcome of these infants (Table 5) .
DISCUSSION
Since the first description of the use of ECMO for newborn respiratory failure by Bartlett et al. 1 in 1976, the use of this technique has become widespread. Survival rates for infants supported with ECMO increased from 55% in 1981 to 86% by late 1980s. The overall survival rate and survival rates for major primary diagnoses of our group of patients are comparable to these reports. Bartlett and Stolar 14 reported that survivors and nonsurvivors differed in birth weight (3.3 Ϯ 0.6 vs 3.0 Ϯ 0.7 kg), gestational age (39 Ϯ 2 vs 38 Ϯ 3 wks), 5-minute Apgar scores (7 Ϯ 2 vs 6 Ϯ 2), and pre-ECMO arterial pH (7.41 Ϯ 18 vs 7.29 Ϯ 0.24) but did not differ in 1-minute Apgar scores, pre-ECMO ventilator settings, and pre-ECMO blood gas measurements other than pH. Weber et al. 15 reported that higher pre-ECMO PaCO 2 and low PaO 2 , and pH were noted to be associated with death among infants with primary diagnosis of meconium aspiration syndrome. In the present study, birth weight, and gestational age were significantly higher among survivors than among nonsurvivors. However, neither the primary diagnosis nor the clinical indicators of illness severity such as 1-and 5-minute Apgar scores, pre-ECMO OI, lowest PaO 2 , and lowest PaCO 2 were different between the two groups.
Follow-up studies of ECMO survivors have reported neurodevelopmental delay in 20% to 40% of infants [2] [3] [4] [5] [6] [7] [8] [9] [10] ; approximately half of these infants have significant handicap with the rest being in the suspect category. The results of our study are consistent with these previous reports. We observed normal neurologic outcome in 81% and normal developmental outcome in 63% of our patients. Thirty-five of 63 (56%) infants had normal neurologic and developmental outcome.
Longer duration of ventilation and oxygen supplementation were associated with abnormal neurodevelopmental outcome in our study. Hyperventilation with induced respiratory alkalosis is a widely practiced therapy for the management of persistent pulmonary hypertension because alkalosis lowers the pulmonary vascular resistance. 16 However, the practice of hyperventilation has been questioned by the reports of comparable survival with less aggressive ventilation and the potential complications of hyperventilation. 17, 18 Hypocarbia following 
N, normal; S, suspect; Ab, abnormal. hyperventilation can have an adverse effect on the cerebral circulation and can lead to central nervous system ischemia. 18 Hyperventilation has been associated with sensorineural deafness and an increase in neurologic impairment in some studies, 19 -21 whereas no adverse effects of hyperventilation were reported in others. 22, 23 Ferrara et al. 22 followed 16 infants treated with hyperventilation for persistent pulmonary hypertension of newborn. They reported that all had normal growth and development, often despite profound or prolonged alkalosis and hypocarbia. In the present study also, the lowest PaCO 2 among infants with adverse neurodevelopmental outcome was not significantly different from that in normal infants. However, in our study infants, the duration of ventilation was significantly longer among infants with abnormal neurodevelopmental outcome as compared with infants with normal outcome. Infants requiring ventilatory support for 15 days or more were at significantly higher risk of having abnormal neurodevelopmental outcome. Similarly, a significantly large proportion of infants who required supplemental oxygen for more than 21 days had an abnormal neurodevelopmental outcome. Glass et al. 5 observed that none of their 25 infants who were normal at 1 year required supplemental oxygen beyond 1 month of age, whereas three of five with supplemental oxygen beyond 1 month were developmentally delayed and the remaining two were suspect. Similarly, Vaucher et al. 10 reported that presence of chronic lung disease significantly increased the risk of adverse neurodevelopmental outcome among ECMO survivors.
Another factor associated with adverse neurodevelopmental outcome was black race. Twenty of 28 (71%) nonblack infants had normal neurodevelopmental outcome as compared with only 15 of 35 (43%) black infants. This difference in neurodevelopmental outcome of black and nonblack infants was predominantly due to cognitive delay in black infants, and the neurologic outcome was comparable in the two groups. The significance of this finding may be limited because the effect of other factors such as marital status, parental education, and family support was not studied and could have played a significant role. Further studies will be helpful in confirming these findings and in identifying the factors that place black infants at risk of abnormal neurodevelopmental outcome following neonatal ECMO.
There was a trend for infants with abnormal neurodevelopmental outcome to require gavage feeding for longer periods than did infants with normal outcome (12.3 Ϯ 4.5 vs 5.1 Ϯ 0.9 days, respectively). Difficulty in establishing full oral feeding is commonly seen in ECMO survivors. It has been reported earlier that most post-ECMO infants have abnormal tone and reflexes for variable period. 24 In their review of neurologic assessment of infants, Casaer et al. 25 reported that the neonatal feeding behavior was a strong predictor of the neurologic functioning at the end of the first year of life and there was a strong correlation with the Mental Developmental Index scores of the Bayley test. They also postulated that the feeding behavior is one of the most complex neonatal behaviors, therefore it correlates more with mental function than with motor function at the end of the first year. However, to the best of our knowledge, there are no reports correlating long-term neurodevelopmental outcome of ECMO survivors with their feeding pattern in neonatal period. The feeding difficulties observed in these infants could either be a sign of central nervous system injury or related to other factors such as manipulation of vagus nerve during cannulation, as suggested by Glass, 24 or due to persistent hypotonia as a result of prolonged use of paralyzing agents such as pancuronium. Further studies will be helpful in re-evaluating the relationship between poor oromotor skills during neonatal period and subsequent neurodevelopmental outcome.
We conclude that the critically ill infants with severe respiratory failure have good survival rates following ECMO. Near term infants with lower birth weight continue to remain at a higher risk of death following ECMO. Follow-up of ECMO survivors demonstrates that these infants are at a significant risk of having subsequent neurodevelopmental delays and thus emphasizes the need for close follow-up of these infants. The need for prolonged respiratory support may help in identifying the "at risk" infants. 
